Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Hannover Medical School

Headquarters: Hannover, Germany
Year Founded: 1965
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jan 28, 2025
Distillery Therapeutics

An allosteric MYO9A and MYO9B inhibitor for cancer metastasis

BioCentury | Jul 18, 2023
Distillery Therapeutics

Microbial polyketide for relapsing C. difficile infection

BioCentury | May 2, 2022
Distillery Therapeutics

Targeting P2Y14 for liver fibrosis

BioCentury | Jun 23, 2021
Product Development

Treg start-ups — who, what and how much: Data Byte

Lining up Treg-focused newcos by their technologies, fundraising, and founders
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

Emerging Company Profile: Syncona’s Quell is developing more targeted Treg cell therapies
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

Emerging Company Profile: Cardior is betting on RNA therapies that aim to help dysfunctional hearts pump more efficiently.
BioCentury | Mar 10, 2020
Product Development

COVID-19 update: gaps persist between U.S. test capacity rhetoric, reality; BARDA funds Hologic’s high-throughput assay

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

BioCentury | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

Items per page:
1 - 10 of 51